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Artificial Pancreas System with Unannounced
Meals based on a Disturbance Observer and
Feedforward Compensation
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Abstract—This paper is focused on closed-loop control of
postprandial glucose levels of patients with type 1 diabetes
mellitus after unannounced meals, still a major challenge towards
a fully autonomous artificial pancreas. The main limitations
are the delays introduced by the subcutaneous insulin phar-
macokinetics and the glucose sensor, which typically lead to
insulin over-delivery. Current solutions reported in the literature
typically resort to meal announcement, which requires the patient
intervention. In this paper, a disturbance observer is used to
estimate the effect of unannounced meals and the insulin phar-
macokinetics is taken into account by means of a feedforward
compensator. The proposed strategy is validated in silico with
the UVa/Padova metabolic simulator. It is demonstrated how the
disturbance observer successfully estimates and counteracts not
only the effect of meals but also sudden drops in the glucose levels
that may lead to hypoglycemia. For unannounced meals, results
show a median time-in-range of 80% in a 30-day scenario with
high carbohydrate content and large intra-subject variability.
Optionally, users may decide to announce meals. In this case,
considering severe bolus mismatch due to carbohydrate counting
errors, the median time-in-range is increased up to 88%. In every
case, hypoglycemia is avoided.
Index Terms—Artificial pancreas, disturbance observer, feed-
forward compensation, type 1 diabetes
I. INTRODUCTION
TYPE 1 diabetes Mellitus (T1DM) is an auto-immunedisorder that destroys the pancreatic β cells, which results
in the incapability of secreting insulin, a hormone that plays
a crucial role in glucose homeostasis as it is responsible of
lowering plasma glucose concentration. Therefore, people with
T1DM generally fail to maintain appropriate glucose levels
and they tend to suffer chronic hyperglycemia, which leads to
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severe health problems in the long term, e.g., cardiovascular
diseases, nephropathy, retinopathy and neuropathy [1]. This is
the reason why exogenous insulin delivery is needed. Open-
loop (manual) control by individuals with T1DM is highly
demanding as it requires carbohydrate counting and a great
number of insulin dosing decisions per day. It is not surprising
then that closed-loop (automatized) insulin delivery has been
an active research field since the 1970s [2], [3], [4]. The device
that performs such task is widely known today as an artificial
pancreas (AP).
In an AP, the insulin dose is computed by a control
algorithm based on glucose measurements coming from a
continuous glucose monitoring (CGM) device and automat-
ically delivered through an insulin pump [5]. There is a
substantial delay between the subcutaneous insulin delivery,
its appearance in the blood stream and, ultimately, its effect
in lowering blood glucose levels. Such long delay typically
causes a feedback controller to over-deliver insulin, resulting
in hypoglycemia, which is the main risk of closed-loop glu-
cose control [6]. Nevertheless, the improvement of an AP in
glucose regulation compared to open-loop therapy is widely
acknowledged [7], [8], [9], [10]. A wide variety of control
strategies have been applied to tackle this problem. Controllers
based on model predictive control (MPC) [11], [12], [13], [14],
proportional-integral-derivative (PID) control [15], [16], fuzzy
logic [17], [18] or linear parameter varying (LPV) models [19],
[20] have been tested in human trials. However, mitigation by
the AP of hyperglycemia due to large meals is still challenging
because of the limitations discussed above. Quite often, current
APs deal with this problem by delivering an insulin bolus
at meal time. However, this requires the patient intervention,
who has to announce the meal and provide an estimate of its
carbohydrate (CHO) content. Misestimation of CHO content
and/or skipping meal announcements is indeed a risk and thus
the controller should be able to handle these situations. In
order to face unannounced meals, heuristic meal detection
and carbohydrate counting algorithms based on CGM readings
have been investigated, which are often used to deliver meal
boluses accordingly [21], [22], [23], [24], [25]. In [19], a meal
detection algorithm is used to trigger a switching controller.
Within the framework of MPC, a switching cost-function
based on the blood glucose rate of change has been employed
in [26].
In the context of control theory, maintaining blood glucose
near the target level can be seen as a standard regulation
problem, in which disturbance rejection is the central issue.
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When disturbances are known, their effect can be mitigated
by means of feedforward compensators [27]. However, quite
often, disturbances cannot be directly measured (for exam-
ple, meals in the application here considered). Disturbance
observers (DOBs) emerged as a powerful tool to estimate
unknown disturbances from other measurable input/output
signals. Then, the estimated disturbance can be used to take
appropriate actions, leading to the so-called DOB-based con-
trol. The reader is referred to [28] for an overview of available
methods. DOB-based controllers have demonstrated simpler
tuning and improved performance over equivalent PID-based
strategies even in high-demanding real-time applications [29].
Furthermore, DOBs to estimate the rate of glucose appearance
have been already designed and successfully validated through
simulations in [30], [31].
In this paper, a DOB-based control strategy is proposed
to deal with unannounced meals. The observer estimates any
unexpected variation in the glucose level by using information
of the CGM, the insulin infusion rate and a control-oriented
nonlinear model of the patient adapted from [12], [32], [33].
The estimation provided by the observer is then combined
with a feedforward strategy to compensate for the delay of the
subcutaneous insulin pharmacokinetics. On the other hand, in
order to handle the constraint of positive control action and
to avoid insulin over-delivery, the insulin feedback strategy
reported in [6] is employed.
II. METHODS
A. Control-oriented patient model
A subject-dependent model is employed for control pur-
poses, adapted from [12], [32]. For each subject j, the follow-
ing switched nonlinear personalized model is considered
Ġ(t) = −(SG(G) + r(G)X(t))G(t) + SG(G)Gb +Ra(t),
Ẋ(t) = −p2X(t) + p2SIcjI(t),
İ(t) = −kII(t) + (1/(tmaxIVI))S2(t), (1)
Ṡ2(t) = −(1/tmaxI )S2(t) + (1/tmaxI )S1(t),
Ṡ1(t) = −(1/tmaxI )S1(t) + ūj(t),
where G (mg/dL) is the plasma glucose concentration, Ra
(mg/dL/min) is the rate of glucose appearance, X (1/min)
is the remote insulin action, I (µU/mL) is the deviation
in plasma insulin concentration, S2, S1 (µU/kg) are the
deviations in insulin amount at each compartment of the
absorption model and ūj (µU/kg/min) is the incremental
infusion rate with respect to the basal insulin infusion
ubj , needed to maintain the fasting glucose value Gb. The
functions r, SG : R
+ → R+ are defined by r(G) = {r if
G ≥ Gb; r if G < Gb} and SG(G) = {SG if G ≥ Gb; SG
if G < Gb}, which are intended to account for the increase
of the insulin action when glucose decreases under a given
threshold towards hypoglycemia (this is a simplification of the
risk function reported in [33]). The individualized parameter








where CRj ,CFj are, respectively, the individual insulin-to-
carbohydrate ratio, given by the simulator, and the correc-
tion factor, computed upon the total daily insulin (TDI) as
CFj = 1800/TDI (this is referred to as the 1800-rule, of-
ten used in conventinal diabetes therapy [34]); and CR =
15.9 g/U, CF = 40.8 mg/dL/U are the mean population values
based on the ten adult virtual subjects of the distribution
version of the UVa/Padova simulator. The factor cj is lower
bounded by 0.7 for safety to avoid too aggressive controllers.
It should be stressed that the use of compact models for
controller design purposes is well celebrated in the field [35],
[36]. More specifically, gain-personalized models have been
previously used in the literature as a useful tool to account
for the variability of total daily insulin requirement among
patients [37], [14], [38]. Moreover, CFj and CRj are clinical
parameters that are known for every patient and thus the
proposed tuning rule would be feasible in a clinical trial.
B. Model identification
A data set for identification was generated using the
UVa/Padova simulator. This data set is based on an open-
loop therapy and it includes meals of different size, bolusing
and changes in the basal rate adjustment, including sinusoidal
variations. Each of the ten adult virtual patients was identified
using the genetic algorithm provided by Matlab R© and pop-
ulation values were obtained by averaging them. The value
r = 1 was set manually to avoid identification problems
because, otherwise, the effect of the insulin sensitivity SI
and the free parameters r, r would be indistinguishable. The
following mean values were obtained: tmaxI = 48.8 min, kI =
0.58 min−1, VI = 28.4 mL/Kg, SI = 6 · 10
−4 mL/µU/min,
p2 = 0.027 min
−1, SG = 0.017 min
−1, SG = 0.007 min
−1
and r = 1.41. It should be remarked that Gb is a control
parameter defining the operating coditions in the absence of
disturbances, which was set to Gb = 100 mg/dL, and the
corresponding basal insulin infusions for each patient, ubj ,
are obtained from the equilibrium equations of the simulator
model [33].
C. Control strategy
The system (1) can be seen as the interconnection between
a nonlinear subsystem, that is, the glucose metabolism, and
a linear subsystem, namely, the insulin pharmacokinetics.
According to this decomposition and defining
x(t) = [X(t), I(t), S2(t), S1(t)]
T ,
the model (1) can be expressed as
Ġ(t) = f(G(t), x1(t), Ra(t)),
ẋ(t) = Ax(t) +Būj(t),
y(t) = x1(t) = X(t),
(3)
where the function f and the matrices A,B are easily obtained
from (1). For the sake of clarity, let us assume for the moment
that both the state x, and the rate of glucose appearance Ra(t),
are known.
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The proposed controller has a cascade structure. First, by
looking at the nonlinear subsystem, the following exponen-
tially stable target system1 given by Ġ(t) = −SG(G)G(t) +
SG(G)Gref (t), is proposed, which can be achieved by choos-











being Gref (t) a piecewise constant function representing the
desired glucose concentration. Second, a tracking controller is
designed so that the error e(t) = x1(t) − x
∗
1(t) approaches
to zero exponentially. To that end, let us consider the trans-
formation z(t) = Tx(t) so that the system in z-coordinates,
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and y(t) = z1(t) = x1(t) = X(t). It is well known that the
transformation matrix is given by T = C(Az, Bz)C(A,B)
−1,
where C denotes the controllability matrix [40]. Once in





























(1)(t) + k1e(t) = 0, (7)
for any set of gains kj > 0. The overall stability of the (G̃, e)-
system, being G̃(t) = G(t) − Gref (t), has a rather common
cascade structure where the exponentially stable e-subsystem
drives the G̃-subsystem. The latter can be cast into a switched
system with vanishing perturbations whose stability is proved
by means of a common Lyapunov function [41], [42].
D. Extended state observer
The controller strategy described above relies on the knowl-
edge of the whole state x and the disturbance Ra. Since these
variables are not measurable in practice, an extended state
observer is adopted to estimate them [28], [30]. Using the



















+ L(G)(y(t)− Ĝ(t)) (8)
where Ĝ, x̂, R̂a are the observer estimates and L : R → R
6 is
the matrix gain to be designed. The proposed observer (8) is
composed of a nonlinear model with a switched linear gain,
1This is a scalar switched system with two exponentially stable modes
whose exponential stability under arbitrary switching is easily proved [39].
L(G) = {L if G ≥ Gb; L if G < Gb}. Each of the gains is
designed by pole placement using the corresponding linearized
model around Gb ± ǫ with ǫ → 0. The closed-loop poles of
the observer are selected according to [30], in order to avoid
overshoot in the estimation.
E. Tracking differentiator
One can see from (6) that the time-derivatives of the target
signal x∗1(t) are also needed. Instead of computing those
numerically, they are rather obtained by means of a simple
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with j ∈ {1, 2, 3, 4} for any ω > 0, which determines the
bandwidth and hence the speed of convergence.
F. Insulin limitation
The proposed control strategy does not take into account the
control input constraint, that is, 0 ≤ u(t) ≤ umax, where u
is the absolute insulin infusion rate. Therefore, an aggressive
tuning of the controller will result in insulin overdose, which
is a known issue in the field of diabetes control [44]. One of
the solutions to mitigate this problem is the insulin feedback
technique, which consists on the inhibition of the insulin
infusion by high values of plasma insulin concentration [6],
[45]. It was pointed out in [45] and validated in clinical
trials in [46], that the insulin located at the subcutaneous
compartments (yet to appear in plasma) could be also included
as an inhibition. Following these ideas, the absolute insulin
rate delivered by the proposed controller is computed by














where γ1, γ2, γ3 > 0 are tuning parameters and Iss =
x1,ss/(cjSI), S2,ss = tmaxIkIVIIss, S1,ss = S2,ss with




/Gref/r(Gref ), are the steady-
state values corresponding to Gref , which are computed from
(1) and (4) assuming Ra(t) = 0.
On the other hand, an upper limit on the maximum insulin
infusion rate is imposed in order to avoid insulin over-delivery
due to very large meals. In practice, this limit is imposed by
the pump capability to deliver insulin and, in any case, it serves
as a safety mechanism. A patient-dependent saturation of the
control action is proposed so that u(t) ∈ [0, (cj/0.7)umax].
Recall that cj is the non-dimensional factor used to personalize
insulin sensitivity in the patient model (1). The individu-
alized bound allows the patient with lowest cj to exploit
the maximum insulin infusion rate umax, and constraints the
other patients proportionally. For this application, the value
umax = 16 U/h is chosen, which corresponds to maximum




MEAL TIMES AND CARBOHYDRATE CONTENT FOR SCENARIOS 1 AND 2
Day 1 Day 2 Day 3
Scenario 1 7h (50g) 14h (60g) 20h (50g) 6h (50g) 13h (70g) 19h (50g) 7h (50g) 13h (65g) 21h (55g)
Scenario 2 7h (50g) 14h (80g) 20h (40g) 6h (50g) 19h (40g) 21h (70g) 7h (50g) 13h (100g) 21h (40g)
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Fig. 1. Closed-loop responses without meal announcement under Scenario 1.
Thick lines are median values while shaded areas embrace the 15% and 85%
percentiles.
G. Glucose target
The use of different glucose targets during nocturnal and
diurnal periods was reported in [14]. This is a safety measure
to reduce the risk of nocturnal hypoglycemia. In this work, a
glucose target of Gref = 130 mg/dL is set for the nocturnal
period (between 23 h and 4 h), whereas Gref = 100 mg/dL
is set during the rest of the day. Notice that the mean values
of the noctural and diurnal target zones reported in [14] are
similar to the target values chosen here.
H. Tuning
The controller gains kj (which determine the closed-loop
bandwidth) are tuned in relation to the tracking differentiator
bandwidth, ω, so that they are the same. A simple way to
achieve this is to select the gains as k1 = ω
4, k2 = 4ω
3, k3 =
6ω2 and k4 = 4ω. Recall that the CGM readings are available
every 5 min, that is, at rate of 1/5 min−1, which already
imposes a limitation on the achievable bandwidth. Based on
this limitation, a closed-loop bandwidth of ω = 1/10 min−1
is selected. Regarding γ1, γ2, γ3, those are selected by trial
and error to avoid insulin overdose without loosing too much
performance. Recall that the factor γ1 inhibits the control
action based on the insulin amount at the first compartment
and hence is the fastest inhibition of all three. Therefore, high
values of γ1 have a large impact on performance in the early
postprandial period. Keeping that in mind, the value of γ1 is
chosen as small as possible. On the other hand, larger values
of γ3 can be set without affecting performance significantly
because its effect takes place after the postprandial peak. The
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Fig. 2. Closed-loop responses without meal announcement under Scenario 2.
Thick lines are median values while shaded areas embrace the 15% and 85%
percentiles.
tuning is performed through simulations with the entire cohort
of patients, in which a meal with a carbohydrate content of
70 g is given. The population values are finally selected as
γ1 = 0.05, γ2 = 0.2 and γ3 = 100, in order to avoid
undershoot in the glucose response (respect to the fasting
value). This tuning is conservative as it ensures safe operating
conditions for every subject of the cohort.
I. Optional hybrid mode
Without meal announcement, the proposed control system
estimates disturbances and delivers insulin accordingly, based
solely on CGM measurements. However, if desired, an AP
system should allow the patient the possibility to announce
meals. In that case, the control law (9) is modified by adding
up the term ubolus(t) = CHO/CR · δ(t− tmeal), where CHO
is the patient’s carbohydrate content estimation, δ(·) is the
Dirac delta function and tmeal is the time when the meal
is announced. Notice that the bolus is computed using only
the meal size and there is no correction term due to neither
the deviation between the glucose target and the current one
nor insulin-on-board. The injection of an insulin bolus causes
a rapid increase in the estimated compartmental and plasma
insulin, leading to a fast inhibition. This mechanism plays the
same role as the insulin on board limitation reported in other
strategies [6], [14].
III. RESULTS
In this section, the proposed strategy is validated in silico
under three different scenarios. Scenarios 1 and 2 are evaluated
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Fig. 3. CVGA plot of comparing the closed-loop responses under Scenario 1
with (blue squares) and without (black circles) meal announcement. Each of
the points at the graph is computed upon 24 h of CGM readings.
using the distribution version of the UVa/Padova simulator
[33]. In order to assess robustness to intra-patient variablity,
a modified version (described below in Section III.C) of
the simulator was used to evaluate Scenario 3. In all three
scenarios, closed-loop control with and without meal an-
nouncement was considered. In the case of announced meals,
CHO misestimation has been simulated according to the study
carried out in [47] (see the curve fitted by regression analysis
in Fig. 3 therein), which basically reports a tendency to
overestimate small meals and underestimate the large ones.
In every simulation, open-loop control with basal insulin rate
is applied during the first 4 h, after which the controller takes
over the insulin delivery [19]. The fasting state of each subject
is taken to start the simulation.
A. Scenario 1
Scenario 1, taken from [19], contains medium-size meals
with a CHO content up to 65 g (see Table I). Breakfast,
lunch and dinner are considered during three consecutive days.
The closed-loop responses (median and 15%-85% percentiles)
without meal announcement for all in silico subjects of the
distribution version of the UVa/Padova simulator under Sce-
nario 1 are shown in Fig. 1. One can see that the proposed
controller has good performance but it still avoids drops near
the hypoglycemic range. Detailed performance indices of the
3-day period can be found in Table II. The overall performance
in this scenario with medium-size meals is very good, scoring
a median time-in-range of 90% and avoiding hypoglycemia.
An average time-in-range of 83% was reported in [19] for
the same scenario, although the size of the virtual cohort
was substantially larger. Another simulation is performed
considering the same scenario with meal announcement. The
comparison is illustrated by means of a Control-Variability
Grid Analysis (CVGA) plot in Fig. 3. Each of the points
depicted in the CVGA plot corresponds to the 2.5% and 97.5%
distribution of CGM data over a 24 h period [48]. One can
see how the points in the CVGA are shifted downwards when
Fig. 4. CVGA plot of comparing the closed-loop responses under Scenario 2
with (blue squares) and without (black circles) meal announcement. Each of
the points at the graph is computed upon 24 h of CGM readings.
meals are announced in spite of the CHO mismatch, leading
also to an outstanding median time-in-range of 99%.
B. Scenario 2
Scenario 2 is based on the previous one and it includes
the following challenging features: i.) large-size meals with
CHO content up to 100 g are included (see Table I); ii.) a
fasting period is considered on the second day in which lunch
is skipped; iii.) a fairly large snack is given shortly before
dinner on the second day ; and iv.) a nocturnal hypoglycemic
episode is simulated by introducing an undetected insulin
bolus of 2 U the first night at 2 AM. The closed-loop responses
under Scenario 2 are shown in Fig. 2. At first glance, the
overall perfornance is also good in spite of the simulated
nocturnal hypoglycemic episode. The postprandial excursions
get further into the hypoglycemic range due to the large-size
Fig. 5. Detail of the first 42 h of the closed-loop response under Scenario 2
(3-day simulation with large-size meals and nocturnal hypoglycemia), for the
virtual subject #2 of the distribution version of the UVa/Padova simulator.
6
TABLE II
OVERALL PERFORMANCE INDICES (MEDIAN VALUES WITH 15% AND 85% PERCENTILES) FOR THE IN SILICO EVALUATION
Scenario 1 Scenario 2 Scenario 3
Announced Unannouced Announced Unannouced Announced Unannouced
Mean BG 128 (123, 130) 136 (125, 140) 130 (123, 132) 138 (126, 142) 135 (128, 144) 144 (131, 153)
% ∈ [70, 180] 99 (97, 100) 90 (83, 98) 93 (90, 98) 85 (83, 95) 88 (80, 94) 80 (74, 88)
% ∈ [80, 140] 71 (69, 84) 65 (59, 76) 72 (71, 79) 65 (59, 74) 66 (58, 71) 57 (50, 68)
% < 70 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0)
% < 60 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
% < 50 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
% > 250 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.5) 0.4 (0.0, 1.7) 0.2 (0.0, 2.0) 1.3 (0.1, 4.2)
% > 300 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.1) 0.0 (0.0, 0.6)
HBGI 1.3 (0.8, 1.6) 2.5 (1.2, 2.8) 1.9 (1.1, 2.1) 3.2 (1.5, 3.8) 2.6 (1.8, 4.0) 3.8 (2.4, 5.0)
LBGI 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.2 (0.1, 0.2) 0.1 (0.0, 0.2)
meals. However, the performance indices (see Table II) are
still fairly good, scoring a median time-in-range of 86% and
avoiding hypoglycemia. The comparison with the announced
scenario is again illustrated by means of a CVGA plot in
Fig. 4, where improvement is also observed, achieving 93%
of median time-in-range.
In order to provide a better insight in how the observer
works, a detailed view of the individual closed-loop response
of patient #2 for the first 42 h is shown in Fig. 5. The meal
glucose rate of appearance (black) and its estimation (blue) are
depicted at the bottom plot. The estimated value aggregates
any unexpected change in the glucose level. That includes
the effect of meals but also model uncertainties and other
disturbances such as induced nocturnal hypoglycemia. One
can see how the estimation drops below zero shortly after
2AM (when the 2U insulin bolus is delivered) leading to a
pump suspension that mitigates that glucose drop. On the other
hand, one can also appreciate in this plot the delay between
the real meal glucose rate and its estimation, which is due
to the sensing delay and observer dynamics. At this point, it
should be remarked that this observer would also estimate a
glucose drop due to exercise, which could be compensated
using specific strategies proposed in the literature [49].
C. Scenario 3
Finally, a third scenario is considered to evaluate the ro-
bustness of the proposed strategy. Scenario 3 has a duration
of 30 days, with three randomized meals per day of 65 g,
70 g, 65 g with a CV = 10% delivered at 7 h, 14 h and
21 h with STD = 60 min, respectively. The scenario also
takes into account large intra-subject variability by varying
insulin absorption model parameters up to ±30% from one
meal intake to another, and insulin sensitivity parameters up to
±30% with a sinusoidal pattern along the day [50]. For intra-
subject meal variability, the ten sets of meal model parameters
of the cohort were randomly assigned to each other at each
meal intake. This is a very challenging scenario in which 35
out of 90 meals have a CHO content over 70 g, being the
average 66.5 g per meal. The results of this simulation are
displayed by means of a CVGA plot in Fig. 6. Without meal
announcement, a few number of samples lay on the out of
the A+B zones, of which approximately 77% correspond to
patient #7 (as pointed out in [38], this patient has an insulin
sensitivity that is not coherent with its TDI). Nevertheless, the
Fig. 6. CVGA plot of comparing the closed-loop responses under Scenario 3
with (blue squares) and without (black circles) meal announcement. Each of
the points at the graph is computed upon 24 h of CGM readings.
overall counting indicates that 91% of the samples lay within
the A+B zones in the unannounced case, which is not far from
the 95% scored in the announced case. It should be pointed out
that the tendency to hyperglycemia in spite of meal boluses is
due to the fact that the simulated uncertainty in CHO counting
severely under-estimates large meals. As indicated in Table II,
the unannounced strategy leads to a median time-in-range of
80%, which is increased up to 88% when meals are announced.
IV. CONCLUSIONS
A novel control algorithm for artificial pancreas system has
been proposed in this work, based on a disturbance observer
and feedforward compensation. It has been shown how the
disturbance observer is capable of estimating disturbances that
cause unexpected variations in glucose levels. That includes
the effect of meals but also model uncertainties or sudden
drops that could result in hypoglycemia. The tuning of the
proposed controller is feasible as it is based on a priori infor-
mation of each subject. For unannounced meals, the results are
promising, showing a median time-in-range of 80% in a chal-
lenging 30-day scenario with high carbohydrate content and
large intra-subject variability. Results show this performance
is further improved by +10% in the same scenario when meals
are announced in spite of severe CHO misestimation.
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While successful postprandial control with meal announce-
ment has been reported, exercise was not discussed in this
work, which is a another major challenge towards a fully
automated artificial pancreas. Future research will be directed
to exploit the information provided by the disturbance observer
in order to mitigate hypoglycemia induced by exercise.
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2007, where he is currently an Associate Professor
within the Department of Systems Engineering and
Control. He has been a visiting researcher at the
Lund Institute of Technology, Sweden, the Uni-
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